scholarly journals The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer

2014 ◽  
Vol 40 (2) ◽  
pp. 293-299 ◽  
Author(s):  
Nuria Ribelles ◽  
Angela Santonja ◽  
Bella Pajares ◽  
Casilda Llácer ◽  
Emilio Alba
Author(s):  
Marina Kochiyeva

Data on modern methodological approaches that are used in screening for cancer are summarized. General principles of organizing screening studies are examined from the perspective of evidence-based medicine, target population, research methods, and effectiveness of the implemented screening programs for breast cancer, cervical cancer, and colon cancer are determined.


Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3688
Author(s):  
Jéssica Fernanda Barazetti ◽  
Tayana Shultz Jucoski ◽  
Tamyres Mingorance Carvalho ◽  
Rafaela Nasser Veiga ◽  
Ana Flávia Kohler ◽  
...  

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.


2021 ◽  
pp. 102229
Author(s):  
Christian Jackisch ◽  
Patricia Cortazar ◽  
Charles E. Geyer Jr ◽  
Luca Gianni ◽  
Joseph Gligorov ◽  
...  

The Breast ◽  
2018 ◽  
Vol 41 ◽  
pp. S15
Author(s):  
Icro Meattini ◽  
Matteo Lambertini ◽  
Isacco Desideri ◽  
Alex De Caluwé ◽  
Orit Kaidar-Person ◽  
...  

Author(s):  
Kristin A. Altwegg ◽  
Ratna K. Vadlamudi

Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70-80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid hormone estrogen [17β-estradiol (E2)] plays a vital role both in the initiation and progression of BC. The E2-ERα mediated actions involve genomic signaling and non-genomic signaling. The specificity and magnitude of ERα signaling are mediated by interactions between ERα and several coregulator proteins called coactivators or corepressors. Alterations in the levels of coregulators are common during BC progression and they enhance ligand-dependent and ligand-independent ERα signaling which drives BC growth, progression, and endocrine therapy resistance. Many ERα coregulator proteins function as scaffolding proteins and some have intrinsic or associated enzymatic activities, thus the targeting of coregulators for blocking BC progression is a challenging task. Emerging data from in vitro and in vivo studies suggest that targeting coregulators to inhibit BC progression to therapy resistance is feasible. This review explores the current state of ERα coregulator signaling and the utility of targeting the ERα coregulator axis in treating advanced BC.


Author(s):  
P. Malathi ◽  
A. Kalaivani

The internet of things is probably one of the most challenging and disruptive concepts raised in recent years. Recent development in innovation and availability have prompted the rise of internet of things (IoT). IoT technology is used in a wide scope of certified application circumstances. Internet of things has witnessed the transition in life for the last few years which provides a way to analyze both the real-time data and past data by the emerging role. The current state-of-the-art method does not effectively diagnose breast cancer in the early stages. Thus, the early detection of breast cancer poses a great challenge for medical experts and researchers. This chapter alleviates this by developing a novel software to detect breast cancer at a much earlier stage than traditional methods or self-examination.


2019 ◽  
Vol 137 ◽  
pp. 143-153 ◽  
Author(s):  
Icro Meattini ◽  
Matteo Lambertini ◽  
Isacco Desideri ◽  
Alex De Caluwé ◽  
Orit Kaidar-Person ◽  
...  

2019 ◽  
Vol 20 (6) ◽  
pp. 1263 ◽  
Author(s):  
Marta Truffi ◽  
Serena Mazzucchelli ◽  
Arianna Bonizzi ◽  
Luca Sorrentino ◽  
Raffaele Allevi ◽  
...  

Cancer-associated fibroblasts (CAF) are the most abundant cells of the tumor stroma and they critically influence cancer growth through control of the surrounding tumor microenvironment (TME). CAF-orchestrated reactive stroma, composed of pro-tumorigenic cytokines and growth factors, matrix components, neovessels, and deregulated immune cells, is associated with poor prognosis in multiple carcinomas, including breast cancer. Therefore, beyond cancer cells killing, researchers are currently focusing on TME as strategy to fight breast cancer. In recent years, nanomedicine has provided a number of smart delivery systems based on active targeting of breast CAF and immune-mediated overcome of chemoresistance. Many efforts have been made both to eradicate breast CAF and to reshape their identity and function. Nano-strategies for CAF targeting profoundly contribute to enhance chemosensitivity of breast tumors, enabling access of cytotoxic T-cells and reducing immunosuppressive signals. TME rearrangement also includes reorganization of the extracellular matrix to enhance permeability to chemotherapeutics, and nano-systems for smart coupling of chemo- and immune-therapy, by increasing immunogenicity and stimulating antitumor immunity. The present paper reviews the current state-of-the-art on nano-strategies to target breast CAF and TME. Finally, we consider and discuss future translational perspectives of proposed nano-strategies for clinical application in breast cancer.


Sign in / Sign up

Export Citation Format

Share Document